daratumumab + belatacept
Phase 1/2Active 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Highly Sensitized Prospective Kidney Transplant Recipients
Conditions
Highly Sensitized Prospective Kidney Transplant Recipients
Trial Timeline
Nov 1, 2021 → Apr 30, 2028
NCT ID
NCT04827979About daratumumab + belatacept
daratumumab + belatacept is a phase 1/2 stage product being developed by Bristol Myers Squibb for Highly Sensitized Prospective Kidney Transplant Recipients. The current trial status is active. This product is registered under clinical trial identifier NCT04827979. Target conditions include Highly Sensitized Prospective Kidney Transplant Recipients.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04827979 | Phase 1/2 | Active |
Competing Products
5 competing products in Highly Sensitized Prospective Kidney Transplant Recipients
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| everolimus + low-dose tacrolimus | Novartis | Phase 2 | 52 |
| Inebilizumab + VIB4920 + Inebilzumab+VIB4920 | Amgen | Phase 2 | 51 |
| carfilzomib + belatacept | Bristol Myers Squibb | Phase 1/2 | 40 |
| UCB0942 | UCB | Phase 2 | 49 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |